Intra-operative interventions for preventing surgical site infection:an overview of Cochrane reviews by Dumville, Jo C. et al.
                          Dumville, J. C., Norman, G., Westby, M. J., Blazeby, J., McFarlane, E.,
Welton, N., ... Liu, Z. (2017). Intra-operative interventions for preventing
surgical site infection: an overview of Cochrane reviews. Cochrane Database
of Systematic Reviews, (5), [CD012653].
https://doi.org/10.1002/14651858.CD012653
Publisher's PDF, also known as Version of record
Link to published version (if available):
10.1002/14651858.CD012653
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Cochrane Library
at http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012653/full. Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Cochrane Database of Systematic Reviews
Intra-operative interventions for preventing surgical site
infection: an overview of Cochrane reviews (Protocol)
Dumville JC, Norman G, Westby MJ, Blazeby J, McFarlane E, Welton NJ, O’Connor L, Cawthorne
J, George RP, Liu Z, Crosbie EJ
Dumville JC, Norman G, Westby MJ, Blazeby J, McFarlane E, Welton NJ, O’Connor L, Cawthorne J, George RP, Liu Z, Crosbie EJ.
Intra-operative interventions for preventing surgical site infection: an overview of Cochrane reviews.
Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.: CD012653.
DOI: 10.1002/14651858.CD012653.
www.cochranelibrary.com
Intra-operative interventions for preventing surgical site infection: an overview of Cochrane reviews (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iIntra-operative interventions for preventing surgical site infection: an overview of Cochrane reviews (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Overview of Reviews Protocol]
Intra-operative interventions for preventing surgical site
infection: an overview of Cochrane reviews
Jo C Dumville1, Gill Norman1, Maggie J Westby1, Jane Blazeby2, Emma McFarlane3 , Nicky J Welton4, Louise O’Connor5, Julie
Cawthorne5, Ryan P George5, Zhenmi Liu1 , Emma J Crosbie6
1Division of Nursing, Midwifery & Social Work, School of Health Sciences, Faculty of Biology, Medicine & Health, University of
Manchester, Manchester Academic Health Science Centre, Manchester, UK. 2NIHR Bristol Biomedical Research Centre, School of
Social & Community Medicine, University of Bristol, Bristol, UK. 3Centre for Guidelines, National Institute for Health and Care
Excellence, Manchester, UK. 4School of Social and Community Medicine, University of Bristol, Bristol, UK. 5Infection Prevention
& Control / Tissue Viability Team, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. 6Division of
Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK
Contact address: Jo C Dumville, Division of Nursing, Midwifery & Social Work, School of Health Sciences, Faculty of Biol-
ogy, Medicine & Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.
jo.dumville@manchester.ac.uk.
Editorial group: Cochrane Wounds Group.
Publication status and date: New, published in Issue 5, 2017.
Citation: Dumville JC, Norman G, Westby MJ, Blazeby J, McFarlane E, Welton NJ, O’Connor L, Cawthorne J, George RP, Liu Z,
Crosbie EJ. Intra-operative interventions for preventing surgical site infection: an overview of Cochrane reviews. Cochrane Database of
Systematic Reviews 2017, Issue 5. Art. No.: CD012653. DOI: 10.1002/14651858.CD012653.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Overview). The objectives are as follows:
To present an overview of the effectiveness and safety of interventions delivered during the intra-operative period aimed at preventing
surgical site infections in all populations under going surgery in operating theatre settings.
B A C K G R O U N D
Description of the condition
Millions of surgical procedures are conducted around the world
each year. Most procedures result in surgical wounds that heal by
primary intention, where wound edges are re-approximated using
sutures, staples, clips or glue. Some surgical wounds are left open
to heal (where closure is not appropriate because of infection,
physical impossibility of approximating wound edges or because
of the need to allow drainage) and some wounds break down
following closure; these open wounds heal from the ’bottom-up’
(known as ’healing by secondary intention’).
Surgical wounds are at risk frommicrobial contamination and thus
possible infection. Contamination may originate from the patient,
for example whenmicrobes on the skin enter a wound, or from the
surrounding environment, for example from operating staff, the
theatre, or wider hospital and home environments. Surgical site
infections (SSIs) are relatively common: a recent US study with
assessment in 183 hospitals involving 11,282 patients found that
452 people (4%) developed hospital-acquired infection; of these,
21.8% were SSIs (Magill 2014). Similar SSI incidence estimates
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have been reported in France (Astagneau 2009). In theUK around
2% to 5% of surgical patients develop SSIs (NICE 2008; Public
Health England 2014) although the percentage varies greatly de-
pending on the circumstances including contamination level of
surgery. In England, a 2006 survey of hospital-acquired infections
reported that 8% of patients in hospitals had an infection while an
inpatient, of which 14% were considered SSIs (Hospital Infection
Society 2007; Smyth 2008). Many quoted incidence estimates for
SSI are likely to be underestimates because infections that devel-
oped outside hospitals were not considered (Bruce 2001; Gibbons
2011). While more data are available for Western healthcare set-
tings, SSI was identified as the leading cause of hospital-acquired
infection in a systematic review of studies in low- and middle-
income countries (Allegranzi 2010).
SSI is a serious global issue which can lead to significant morbid-
ity, need for re-intervention and treatment (including antibiotic
use), delayed wound healing, and in very serious infections, the
possibility of death (Awad 2012; Brown 2014; CDC 2017). SSIs
also increase consumption of healthcare resources. Recent figures
from the UK suggest that SSIs lead to a median increased hospital
stay of 10 days (96% CI 7 to 13 days) with an associated median
additional cost attributed to SSI ofGBP 5239 (95%CIGBP 4622
to 6719) (Jenks 2014). The UKNational Institute for Health and
Care Excellence (NICE) identified that an SSI increased the costs
of surgery by two to five times (NICE 2008). In the USA, De
Lissovoy 2009 estimated that the extended length of stay and in-
creased treatment costs associated with SSIs over a one-year period
led to approximately 1 million additional inpatient-days, costing
an additional USD 1.6 billion.
SSI risk
The patient’s overall physical health can predict the risk of SSI, as
can the type of surgical procedure (in terms of potential for con-
tamination) and duration of surgery. These factors are collectively
included in the National Nosocomial Infections Surveillance risk
index (Gaynes 2001; SWI Task Force 1992) which proposes three
criteria to assess risk: American Society of Anesthesiologists (ASA)
score of 3, 4, or 5 (ASA 2017); wound class (see below); and du-
ration of surgery. Other risk factors for SSI are suggested; such as
if surgery is elective or emergency, but supporting data for these
risk factors are more limited.
Wound class
Wound class is assessed using the classification system adopted by
the Centres for Disease Control and Prevention (HICPAC 1999):
• Clean: non-infective operative wounds in which no
inflammation is encountered, and neither the respiratory,
alimentary, genito-urinary tract nor the oropharyngeal cavity is
entered. In addition these cases are elective, have primary
closure, and wounds are drained with closed drainage systems
when required.
• Clean/contaminated: operative wounds in which the
respiratory, alimentary, genital or urinary tract is entered under
controlled conditions and without unusual contamination.
Specifically, operations involving the biliary tract, appendix,
vagina and oropharynx are included in this category, provided no
evidence of infection or a major break in sterile technique is
encountered.
• Contaminated: fresh, accidental wounds, operations with
major breaks in sterile technique or gross spillage from the
gastro-intestinal tract, and incisions in which acute, non-
purulent inflammation is encountered.
• Dirty: old traumatic wounds with retained devitalised
(dead) tissue and those that involve existing clinical infection or
perforated viscera (internal organs or gut). This definition
suggests that organisms causing postoperative infection were
present in the operative field before the operation.
In the UK data from 232 NHS hospitals on 620,535 surgical
procedures reported SSI rates of: 0.5% for knee prosthesis; 1% for
cardiac surgery (non-coronary artery bypass graft); 0.6% for hip
prosthesis and 5% for limb amputation (all clean surgery) (Health
Protection Agency 2015). This is in contrast to the incidence of
SSI following surgery on the large bowel (contaminated surgery) of
9.7% (Health Protection Agency 2015). Europe-wide surveillance
also reports higher incidence of SSI in colon surgery (9.5% of
surgeries resulting in SSI) (ECDC 2013).
Defintion of SSI
Although there is no single agreed diagnostic tool or protocol to
confirm the presence of an SSI (Bruce 2001 identified 41 different
definitions for SSI and 13 grading scales), the Centers for Disease
Control and Prevention (CDC) definition is commonly used (
Horan 1992):
A superficial SSI is defined as: an infection occurring within 30
days after the operation and only involving the skin and subcuta-
neous tissue of the incision that is associated with at least one of
the following:
• purulent drainage, with or without laboratory
confirmation, from the surgical site;
• organisms isolated from an aseptically-obtained culture of
fluid or tissue from the surgical site;
• at least one of the following signs or symptoms of infection:
pain or tenderness, localised swelling, redness or heat, and
superficial incision is deliberately opened by the surgeon and is
culture-positive or not cultured. A culture-negative finding does
not meet this criterion;
• diagnosis of SSI by the surgeon or attending physician.
A deep incisional SSI is defined as: infection that occurs within
30 days after the operative procedure if no implant is left in place,
or within one year if an implant is left in place, and the infection
appears to be related to the operative procedure and involves deep
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soft tissues (e.g. fibrous connective tissues and muscle layers) of
the incision associated with one of the following:
• purulent drainage from the deep incision, but not from the
organ/space component of the surgical site;
• a deep incision spontaneously dehisces (opens up) or is
deliberately opened by the surgeon and is culture-positive or not
cultured when the patient has at least one of the following
symptoms: fever or localised pain or tenderness;
• an abscess, or other evidence of infection involving the deep
incision is found on direct examination, during re-operation, or
by histopathologic or radiologic examination;
• diagnosis of a deep incisional SSI by a surgeon or attending
physician.
Description of the interventions
Many interventions are used with the aim of reducing the risk of
SSI in people undergoing surgery. These interventions can be de-
livered at three stages: pre-operatively, intra-operatively and post-
operatively (Goodman 2016). For the purpose of this review we
define:
• the pre-operative phase as the time period between the
decision for the need for surgery and when everything is ready
for the operation to start i.e. the patient is on the operating table
(for this review we have assumed that staff are ready to proceed
with surgery at this point - thus the preparation of operative staff
occurs in this pre-operative period);
• the intra-operative phase as the time period from when the
patient is on the operating table to when the operation has
finished and the wound is closed (if relevant). We consider any
activity listed to take place at induction of anaesthesia in this
phase;
• the postoperative phase as the time period from the end of
the intra-operative phase to resolution of surgical procedure
(which we acknowledge could take several, weeks or months for
some patients). We note that whilst dressings, wound drains and
negative pressure wound therapy are often placed over wounds at
the end of surgery, their use is predominantly outside of theatre,
so they are considered in the postoperative phase.
Table 1 details key intervention types used at each stage of the
operative pathway, but is not an exhaustive list.Most interventions
listed are probably independent of each other and would generally
be delivered concurrently. However, the interventions listed could
also be grouped together as a care bundle, where a care bundle is
defined as a group of three to five evidence-based interventions
that are delivered together.
This overview of reviews will focus on interventions delivered in
the intra-operative phase
How the intervention might work
See Table 1. The interventions are largely focused on decontami-
nation of skin using soap and antiseptics; the use of barriers to pre-
vent movement of micro-organisms into wounds; and optimising
the patient’s own bodily functions to promote best recovery. Both
decontamination and barrier methods can be aimed at people un-
dergoing surgery and operating staff. Other interventions focused
on SSI prevention may be aimed at the surgical environment and
include methods of theatre cleansing and approaches to theatre
traffic (i.e. how the movement of staff in and out of theatre is
managed).
Why it is important to do this overview
The Cochrane Handbook describes a Cochrane overview of
reviews as being “intended primarily to summarize multiple
Cochrane Intervention reviews addressing the effects of two or
more potential interventions for a single condition or health prob-
lem” (Becker 2011).
SSIs are a prevalent problem for global healthcare and their pre-
vention is a major focus for healthcare providers internationally.
There are over 20Cochrane reviews that draw together randomised
controlled trial evidence for individual prophylactic SSI inter-
ventions along the pre-operative, intra-operative and postoper-
ative pathway. Findings from these reviews have not been col-
lated, so a transparent and usable synthesis of this evidence is re-
quired. This overview will aid decision makers aiming to draw
together Cochrane evidence that spans the SSI prevention path-
way. It will also be a useful resource for guideline developers, es-
pecially for the key National Institute for Health and Care Excel-
lence (NICE) guidelines which have not been fully updated for
several years (NICE 2008). (A planned update of the guidelines
was announced in 2017). This overview will also complement
other guidelines such as those produced by the World Health Or-
ganization (Allegranzi 2016a; Allegranzi 2016b).
O B J E C T I V E S
To present an overview of the effectiveness and safety of interven-
tions delivered during the intra-operative period aimed at prevent-
ing surgical site infections in all populations under going surgery
in operating theatre settings.
M E T H O D S
Criteria for considering reviews for inclusion
Types of studies
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We will include reviews published in the Cochrane Database of
Systematic Reviews that examine the effectiveness of interventions
aimed at preventing surgical site infections (SSIs). We will not
consider non-Cochrane reviews. We will only include systematic
reviews of randomised controlled trial (RCT) evidence for pa-
tient-focused interventions. If reviews include other study designs
alongside RCTs (e.g. controlled clinical trials, quasi-randomised
controlled trials, or both) we will investigate if RCT evidence is
presented separately for relevant analyses (e.g. as sensitivity anal-
yses). If so, these RCT data will be included. If there are no sepa-
rate data for RCTs in a review of patient-focused interventions we
will not include that review in analyses. Primary RCTs published
since the included reviews, but not yet included in reviews, will
be excluded in line with Cochrane guidance.
Where studies evaluate service-level interventions e.g. protective
staff coverings, theatre traffic and environmental cleansing, designs
such as interrupted time series and controlled before and after
studies are more feasible and we will also extract data from these
study designs as well as from RCTs (including cluster RCTs).
Types of participants
We will include reviews of studies involving adults or children or
both. We will exclude reviews where inclusion criteria specified
that study participants had infected wounds at baseline (i.e. treat-
ment rather than prevention reviews). Reviews that considered
both treatment and prevention studies will be examined in detail
to isolate relevant comparisons.
We will include reviews of participants undergoing surgery of any
contamination level (clean, clean/contaminated, contaminated
and dirty). Reviews focused solely on graft sites and wounds of the
mouth and eye will be excluded. We will include reviews looking
at surgical wounds planned to heal by primary intention (closed
wounds) and secondary intention (openwounds). Given their spe-
cialist nature, we will exclude eye and oral surgeries and studies
looking at infection prevention in pin sites.
Types of interventions
We will include reviews that assessed the following interventions
aimed at preventing SSIs during the intra-operative period of the
patient care pathway (regardless of comparator - all are eligible):
• decontamination of patients’ skin at site of surgery incision;
• use of intra-operative prophylactic antibiotics;
• skin sealants;
• use of standard and incise drapes;
• use of masks, hair covers, overshoes, gowns and other
protective coverings for theatre staff;
• different glove protocols;
• use of electrosurgery for surgical incisions;
• maintaining patient homoeostasis (warming);
• maintaining patient homoeostasis (oxygenation);
• maintaining patient homoeostasis (blood glucose control);
• wound irrigation and intracavity lavage (including use of
intra-operative topical antiseptics before wound closure);
• closure methods;
• theatre traffic (protocols for managing the movement of
people in theatre).
We will exclude reviews focusing on comparison of different sur-
gical approaches for the same surgery (e.g. different techniques for
inguinal surgical repair; open versus closure of perianal wounds)
or other interventions specific to certain types of surgery or pro-
cedures. We will also exclude studies comparing different anaes-
thesiology regimens and those investigating the use of implants or
internal devices.
Where interventions are delivered at multiple time periods in the
same studies, such as for assessment of antibiotics where treatment
is started in one phase and continued through multiple phases
(e.g. antibiotics started pre-operatively and continued postoper-
atively), data will be presented in the overview that correspond
with the start of the treatment. Thus this intra-operative overview
will include reviews where the start of treatment is in the intra-
operative phase. Where a review contains trials that variously de-
liver interventions at different starting phases we will aim to ex-
tract and present data for only those trials relevant to the intra-
operative phase (that is where the treatment starts in the intra-
operative phase).
Types of outcomes
We will present data according to the time points used in reviews
(if reported). Where possible, we will group data into follow up
of 30 days or less and follow up of more than 30 days. If a review
presents data at many different time points, the overview authors
may report data from the time points closest to 30 days and one
year, notingwhere other time point data are available in the original
review.
Primary outcome
SSIs: occurrence of postoperative SSI as defined by the CDC
criteria (Horan 1992), or the study authors’ definition of SSI.
Where available we will present data that differentiates between
superficial and deep-incisional infection.
Secondary outcomes
Mortality: postoperative mortality.
Health-related quality of life:wewill include quality of life assess-
ments where they are reported using a validated scale that presents
a single global score (e.g. SF-12, SF-36 or EQ-5D) or a validated
disease-specific questionnaire. Ideally, reported data will be ad-
justed for baseline scores. We will not include ad hoc measures of
quality of life that were not likely to be validated and would not be
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common to more than one trial. We will not report on multiple
domain scores for validated measures.
Cost-effectiveness: findings that consider relative costs and ben-
efits simultaneously.
Search methods for identification of reviews
We will search the Cochrane Database of Systematic Reviews using
the search strategy presented in Appendix 2. Given the large num-
ber of interventions relating to the review, the search terms focus
on identification of reviews linked to surgical site infection rather
than to specific interventions.
Data collection and analysis
Selection of reviews
Two overview authors will screen review titles and abstracts to
identify potentially relevant inclusions. All reviews thought to be
potentially eligible will be obtained in full text for further investi-
gation. The same two overview authors will screen the full text of
all potentially relevant resources for inclusion in the overview. We
will record reasons for exclusion of any reviews excluded at this
stage. Any disagreements will be resolved through discussion with
a third overview author. Where overview authors are also authors
of included reviews we will seek to avoid bias by ensuring that
decisions are made by two other overview authors.
Data extraction and management
We will extract data into a predefined and piloted data extrac-
tion form to ensure consistent data capture from each resource.
Data will be extracted by one overview author and independently
checked by a second, with a third acting as arbiter where required.
We will extract the following data for each included resource:
1. study identification, review authors’ details;
2. review objectives;
3. review inclusion and exclusion criteria;
4. included settings;
5. included populations, including types of surgery or
procedure and depth of incision;
6. all relevant comparisons and associated time points;
7. concurrent intervention types that were the same for all
intervention arms;
8. numbers of relevant included RCTs;
9. outcomes reported and details of reported outcome values;
10. method and results of risk of bias and evidence quality
assessment;
11. GRADE assessments;
12. details of any subgroup and sensitivity analyses.
Where a comparison is included in more than one review, the
details will be recorded multiple times (because it is relevant to
each review in which it is contained). However, we will report the
comparison only once for the review with the lowest risk of bias,
or the most recent review if there is no difference in risk of bias
assessment. We will extract meta-analysed data where possible and
single study datawhen pooled data are not available: wewill extract
effect sizes with 95% confidence levels where possible. We will also
extract contextual information to enable narrative descriptions of
how data were pooled (or not) presented per comparison (e.g. if
some trials have been pooled for a comparison and some have
not). If any information from a review is unclear or missing, we
will access the published reports of the individual trials. We do
not plan to contact study authors for details of missing data, but
rather will assume that review authors had done all they could to
retrieve data. We will enter data into Review Manager 5 software
(RevMan 2014).
Assessment of methodological quality of included
reviews
Quality of included Cochrane reviews
We will assess the risk of bias of each included review using the
ROBIS tool (Whiting 2016) which focuses on four key domains:
• study eligibility criteria;
• identification and selection of studies;
• data collection and study appraisal; and
• synthesis and findings.
Each domain contains a list of signalling questions to guide the
bias assessment process. The signalling questions can be answered
yes, probably yes, probably no, no or no information. Questions
are worded so that a yes response relates to low concerns about
the review e.g. “Did the review adhere to pre-defined objectives
and eligibility criteria? and were the eligibility criteria appropriate
for the review question?” At the end of each domain the assessor
draws together their appraisal to indicate their concerns regard-
ing: specification of study eligibility (domain 1); methods used to
identify and select studies, or both (domain 2); methods used to
collect data and appraise studies (domain 3); and the synthesis and
findings (domain 4). Concerns can be graded low, high or unclear.
The final phase of assessment using the ROBIS tool involves al-
locating an overall risk of bias judgement for the review (graded
high, low or unclear) using the following signalling questions.
• Did the interpretation of findings address all of the
concerns identified in domains 1 to 4?
• Was the relevance of identified studies to the review’s
research question appropriately considered?
• Did the reviewers avoid emphasising results on the basis of
their statistical significance?
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The rationale or reasoning for decisions at each stage, that is for
the signalling questions and the level of concern rated, will be
recorded in a table for each domain. We will aim to present a
summary of ROBIS results for each review either using the sug-
gested approach (a circle with five coloured segments per review)
or coloured symbols in a table format which we think will lend
itself to presentation of data for a large number of reviews.
We note that the ROBIS tool also contains an optional first phase
called assessing the relevance.Wedonot anticipate using this phase
because the relevance will be considered as part of our screening
and selection process.
Quality or certainty of evidence extracted from included
reviews
It is important to present the quality or certainty of evidence from
each review. We will present a GRADE assessment for each eli-
gible outcome and comparison. Where GRADE assessment was
conducted in the review we will extract this assessment; however,
where GRADE assessments are not available, the overview authors
will undertake assessment (making it clear that the GRADE as-
sessment was conducted post hoc).
Whenmaking decisions for the risk of bias domain, we will down-
grade one level when studies have been classified at high risk of
bias for one or more domains and where they were classified at
unclear risk of bias for both domains that contributed to selection
bias, or both.
In assessing the precision of effect estimates for SSI we will
follow GRADE guidance (GRADE 2013; Schünemann 2011a;
Schünemann 2011b).We plan to take a conservative approach and
will calculate an optimal information size (OIS) for the SSI out-
come using conventional sample size calculation methods and as-
suming a relative risk reduction of between 20% and 30% (Guyatt
2011). The OIS is summarised below but should not be treated
as optimal sample sizes for any future research. In GRADE assess-
ments, theOIS is used to assess the stability of confidence intervals
(CI) rather than to assess the appropriateness of a sample size to
detect a difference per se.
Reduction in SSI from 14% to 10% (80% power; alpha 5%) =
2070 participants. Although on average, SSI rates are lower than
14% in many developed countries, they can be higher in some
countries and figures vary by SSI risk of the patient.We have taken
14% as a conservative upper estimate of SSI incidence and will
calculate 40% relative risk reduction.
We will use the GRADE default minimum sample size for di-
chotomous outcomes of 300 in lieu of the OIS to assess precision
for mortality.
If the OIS is not met we will downgrade one level. We will down-
grade two levels if there are very few events (or very few partici-
pants for continuous outcomes). If the OIS is met we will down-
grade one level if the 95% CI fails to exclude important benefits
and harms which we will consider as a relative risk reduction or
increase of 25%.
Data synthesis
The aim of this review is to present a detailed summary of treat-
ment effect data for interventions aimed at SSI prevention.We an-
ticipate presenting all relevant comparisons grouped by interven-
tion type (including details of co-interventions when recorded).
We will also consider data according to the contamination level of
surgery where possible.Wewill use tabular formats to present sum-
maries of treatment effects with a corresponding GRADE assess-
ment for each comparison. Where possible we will extract meta-
analysed data, along with details of model type and measures of
statistical heterogeneity. Where data have not been meta-analysed
we will report study-level treatment effects. Results from review
subgroup and sensitivity analyses will also be presented. We antic-
ipate that most, if not all, results will be presented in tabular and
narrative formats. An example of the type of table we plan to use
to present results is presented as Table 2.
Where applicable, we will convert available data to risk ratio (RR).
Where this is not possible we will present original data. We do not
plan to undertake re-analysis of data beyond conversions to RR
and are not planning to undertake a network meta-analysis within
given intervention types.
Elements of this protocol are drawn from related protocols and
reviews by the authors (Dumville 2016;Norman 2015;Wu2015).
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A D D I T I O N A L T A B L E S
Table 1. Interventions aimed at preventing surgical site infections
Intervention Details Theories on how the intervention type
might work
Intra-operative intervention types Intra-operative inter
Decontamination of patients’ skin at site of
surgery incision
(for the patient)
Before surgery, patients’ skin is disinfected
using antiseptic solutions such as povidine-
iodine or chlorhexidine at varying concen-
The aim of preoperative skin antisepsis is
to reduce the risk of SSIs by reducing the
number of microorganisms on the skin (
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Table 1. Interventions aimed at preventing surgical site infections (Continued)
trations ACORN 2012; Mangram 1999).
Skin sealants
(for the patient)
Microbial sealants are liquids that are ap-
plied to the patient’s skin before surgery
and left to dry forming a protective film
over the planned incision site. Cyanoacry-
late, which is also used as a tissue adhesive,
can be used as a skin sealant
As with other barrier methods, the use
of skin sealants is focused on preventing
contamination of the surgical wound with
micro-organisms from the patient’s skin.
It is proposed that skin sealant use be-
fore surgery prevents any remaining micro-
organisms from migrating into the surgi-
cal wound following skin decontamination
(Singer 2008).
Incise drapes
(for the patient)
Before a surgical incision is made, ster-
ile plastic adhesive (incise) drapes can be
placed onto cleansed skin. The surgical in-
cision is then made through the drape.
Drapes can be plain or impregnated with
antimicrobial products
Drapes are used as a barrier between the
incision and the patient’s skin, which al-
though cleansed, may harbour micro-or-
ganisms, such as at deeper levels of the
skin that cleansing cannot reach (Swenson
2008).
Use of masks, hair covers, overshoes, gowns
and other protective coverings for theatre
staff
(for staff )
Protective coverings worn in theatre by staff
to limit the movement of micro-organisms
in theatre (Cooper 2003).
For example: masks over the face; dis-
posable shoe covers worn over standard
footwear and changed as required; dispos-
able or re-usable gowns worn over standard
scrub outfits and changed as required
There are various coverings used in surgery
that are designed to act as a barrier between
the environment and the patient’s wound
to maintain a sterile operative field, such as
masks that aim to capture water droplets
being expelled. Masks contain one or two
very finely woven filters that can inhibit
bacteria. Masks cover the nose and mouth,
but there is concern that masks may be
worn incorrectly and allow air leaks from
the sides of the mask
Shoe coverings aim to limit the transfer of
external material in and out of theatres
Gowns cover standard surgical attire and
can be removed when contaminated and
replaced
Different glove protocols
(for staff )
Surgical staff wear disposable gloves dur-
ing surgery. Gloves are used in a number of
ways intended to minimise microbial con-
tamination from staff to patients, including
double gloving (using two pairs of gloves),
the use of glove liners or cloth outer gloves
(Kovavisarach 2002; Laine 2004).
Gloves are a barrier intervention that aim to
prevent transfer of micro-organisms from
the staff member’s skin to the patient’s skin
or wound. Gloves also act as a barrier to
prevent staff from infection by patients
Use of electrosurgery for surgical incisions
(for the patient)
In electrosurgery, an electric current is used
to generate heat which vaporises cellular
material, cutting the skin in place of a
scalpel. This can be used to cut skin from
the top surface down or used on deep skin
It has been suggested that using heat to
make a surgical incisionmay reduce the risk
of SSI
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Table 1. Interventions aimed at preventing surgical site infections (Continued)
layers once an incision has been made with
a scalpel (Soderstrom 2003).
Maintaining patient homoeostasis (warm-
ing)
(for the patient)
During surgery the patient’s bodily func-
tions need to be optimised to promote re-
covery; it is further postulated this may also
reduce the risk of SSI. Under general anaes-
thetic it is harder for the body to regulate its
own temperature and this can increase the
risk of peri-operative hypothermia. Warm-
ing can be achieved using thermal insula-
tion such as blankets, or active methods
of warming that use machines to transfer
heat to the patient, and use of heated intra-
venous fluids (NICE 2016;Whitney 2015)
.
Undertaking warming aims to maintain
body temperature and prevent the de-
velopment of peri-operative hypothermia
which can lead to negative postoperative
outcomes, which potentially include SSI.
These interventions can also be used post-
operatively to mitigate the impact of peri-
operative hypothermia when it has not
been prevented
Maintaining patient homoeostasis (oxy-
genation)
(for the patient)
During surgery under general anaesthetic
patients are intubated and supplied with
oxygen to maintain adequate oxygen per-
fusion to all tissues
It is suggested that the risk of SSI is higher
when tissue oxygenation is not optimised
during surgery. Some surgical protocols use
higher saturation levels of oxygen during
intubation to increase tissue oxygenation
levelswith the aimof reducingwound com-
plications such as SSI. High oxygen levels
have been linked to serious adverse events
such as blindness and death (Al-Niaimi
2009).
Maintaining patient homoeostasis (blood
glucose control)
(for the patient)
Use of strict glycaemic control using med-
ications to maintain glucose levels during
surgery
Hyperglycaemia after surgery is postulated
to lead to increased risk of surgical com-
plications including infection (Ljungqvist
2005; Stephan 2002).
Wound irrigation and intracavity lavage
(including use of intra-operative topical an-
tiseptics before wound closure)
(for the patient)
Surgical irrigation and intracavity lavage
use fluids to wash out the surgical cavity
at the end of the surgical procedure before
the wound is closed. Both wound irriga-
tion and intracavity lavage can be altered
by: volume of irrigation fluid; mechanism
or timing of delivery; or solution composi-
tion (Barnes 2014).
The theoretical advantage of surgical
wound irrigation is to reduce the bacte-
rial load in a surgical wound, and thus the
risk of SSI, through a combination of wa-
ter pressure, dilution, or the application of
antimicrobial agents
Closure methods
(for the patient)
Surgical wounds canbe closed using sutures
(absorbable or not) staples, adhesive strips
or tissue adhesives. Some closure methods
can make use of sutures that are coated in
antimicrobial products
The timing of closure can also vary; some
wounds canbe left open for a period follow-
There is a view that the method of surgi-
cal wound closure may impact on SSI risk.
There is limited background evidence on
mechanisms for SSI prevention, although
it has been suggested that the better the
seal the closure method obtains, the bet-
ter the barrier to microbial contamination
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Table 1. Interventions aimed at preventing surgical site infections (Continued)
ing surgery and then closed (delayed clo-
sure)
(Gurusamy 2014).
Theatre cleansing
(for the environment)
The theatre environment needs to be
cleaned regularly with detergents to disin-
fect surfaces. Daily deep cleaning is likely
to occur using various protocols for clean-
ing surfaces between patient surgeries, es-
pecially areas that are contaminated with
bodily fluid, or that are frequently touched
by staff. Recent technologies used for the-
atre cleansing include UVC light decon-
tamination and hydrogen peroxide vapour
treatment
Surgical instruments are also sterilised to
decontaminate them after use. Various pro-
tocols are used including steam sterilisation
and chemical sterilisation, which is used
when steam sterilisation is not feasible
Theatre cleaning can also involve the use of
ventilation systems, such as laminar airflow
systems, which supply filtered air into the
environment to limit numbers of airborne
micro-organisms
To avoid cross-infection, special protocols
may be developed for cleansing when sur-
gical patients are known to have specific in-
fections
All aspects of theatre cleansing aim to min-
imise numbers of micro-organisms present
in the theatre environment with the aim of
reducing the risk of SSI. (Spagnolo 2013).
Theatre traffic
(for the environment)
A surgical theatre can be a busy working
environment with people moving in and
out. This movement can be managed, for
example limiting the entrance and exit of
staff during surgery, and minimising visi-
tors into the theatre (e.g. partners ofwomen
undergoing caesarean sections) (Spagnolo
2013).
A key aim in the prevention of SSI is to
limit numbers of micro-organisms in the
operative environment. People moving in
and out of the operative field may increase
the risk of contamination. Visitors to the
theatre who have not undergone full hand
scrubbing protocols and so forth could also
potentially increase SSI risk
Table 2. Example overview of review summary of findings table
Interventions for [condition] in [population] Interventions for
in [population]
Outcome Intervention
and Compar-
ison interven-
tion
Illustrative comparative risks
(95% CI)
Relative ef-
fect (95% CI)
Num-
ber of partic-
ipants (stud-
ies)
Quality of the
evidence
(GRADE)
Comments
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Table 2. Example overview of review summary of findings table (Continued)
Assumed risk Correspond-
ing risk
With
comparator
With
intervention
Outcome #1 Outcome #1
Intervention/
comparison #
1
Intervention/
comparison #
2
Outcome #2 Outcome #2
Intervention/
comparison #
1
Intervention/
comparison #
2
Outcome #3 Outcome #3
Intervention/
Comparison #
1
Intervention/
Comparison #
2
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A P P E N D I C E S
Appendix 1. Summary of common topical antiseptics used in pre-operative skin decontamination
Antiseptic agents
Alcohol
Alcohol denatures the cell wall proteins of bacteria. Alcohol rubs are usually available in preparations of 60% to 90% strength and are
effective against a wide range of gram-positive and gram-negative bacteria, M ycobacterium tuberculosis, and many fungi and viruses.
The three main alcohols used are ethanol, isopropanol and n-propanol, and some rubs may contain a mixture of these. Alcohol-based
solutions usually (but not always) contain additional active ingredients to combine the rapid bacteriocidal effect of alcohol with more
persistent chemical activity.
Iodine and iodophors
Iodine and iodophors are iodine solutions which are effective against a wide range of gram-positive and gram-negative bacteria, the
tubercle bacillus (TB), fungi and viruses. These penetrate cell walls, then oxidise and substitute the microbial contents with free iodine
(Hardin 1997; Mangram 1999; Warner 1988). Iodophors contain a surfactant or stabilising agent that liberates the free iodine (Wade
1980). Iodophor has largely replaced iodine as the active ingredient in antiseptics. Iodophor comprises free iodine molecules bound
to a polymer such as polyvinyl pyrrolidine (i.e. povidone), so is often termed povidone iodine (PI) (Larson 1995). Typically, 10%
PI formulations contain 1% available iodine (Larson 1995; Reichman 2009). PI is soluble in both water and alcohol, and available
preparations include aqueous iodophor scrub and paint, aqueous iodophor one-step preparation with polymer (3M), and alcoholic
iodophor with water insoluble polymer (DuraPrep).
Chlorhexidine
Chlorhexidine is a biguanide. It is effective against a wide range of gram-positive and gram-negative bacteria, lipophilic viruses and
yeasts. Although its immediate antimicrobial activity is slower than alcohols, it is more persistent because it binds to the outermost
layer of skin.
Triclosan
Triclosan (2,4,4’-trichloro-2’-hydroxydiphenyl ether) has been incorporated in detergents (0.4% to 1%) and alcohols (0.2% to 0.5%)
used for hygienic and surgical hand antisepsis or pre-operative skin disinfection. It inhibits S taphylococci, coliforms, enterobacteria and
a wide range of gram-negative intestinal and skin flora.
Appendix 2. Search strategy
#1MeSH descriptor: [Surgical Wound Infection] explode all trees
#2MeSH descriptor: [Surgical Wound Dehiscence] explode all trees
#3(surg* near/5 infect*):ti,ab,kw
#4(surg* near/5 wound*):ti,ab,kw
#5(surg* near/5 site*):ti,ab,kw
#6(surg* near/5 incision*):ti,ab,kw
#7(surg* near/5 dehisc*):ti,ab,kw
#8(wound* near/5 dehisc*):ti,ab,kw
#9(wound* near/5 infect*):ti,ab,kw
#10(wound near/5 disruption*):ti,ab,kw
#11(wound next complication*):ti,ab,kw
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